CANWELL BIOTECH Ltd., founded in June 2018, is an innovative drug research and development company, focusing  on the development and commercialization of anti-tumor First-in-Class and Best-in-Class immunotherapies. By harnessing both innate and adaptive immune responses against tumor cells. CanWell is building its immuno-oncology product platforms through 2 lead programs,  CAN1012, a TLR7 agonist, and DPV-001, a dendritic cell targeted cancer vaccine.